• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

台湾肺黏液腺癌的多驱动基因突变分析:罕见的CD74-NRG1易位病例的鉴定

Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.

作者信息

Gow Chien-Hung, Wu Shang-Gin, Chang Yih-Leong, Shih Jin-Yuan

机构信息

Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, 220, Taiwan.

出版信息

Med Oncol. 2014 Jul;31(7):34. doi: 10.1007/s12032-014-0034-4. Epub 2014 Jun 10.

DOI:10.1007/s12032-014-0034-4
PMID:24913807
Abstract

Several new chromosomal translocations resulting in driver fusion mutations have recently been discovered in non-small-cell lung cancer. The driver mutational patterns in pulmonary mucinous adenocarcinoma, a rare subtype of non-small-cell lung cancer, have not been well studied. A single-institute cohort study in Taiwan was performed to determine the mutations of epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), fusions of anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), and neuregulin 1 (NRG1) in patients diagnosed with pulmonary mucinous adenocarcinoma. We also examined NRG1 translocation in patients diagnosed as adenocarcinoma of other subtypes with wild-type EGFR, KRAS, ALK, and ROS1 genes. Surgical or biopsy specimens were collected from 13 patients with mucinous adenocarcinoma. Using the direct RNA sequencing method, we discovered a rare CD74-NRG1 fusion (8 %), an echinoderm microtubule-associated protein like 4 (EML4)-ALK fusion (17 %), and three KRAS mutations (25 %). No EGFR mutations or ROS1 rearrangements were detected. The rare CD74-NRG1 fusion positive patient presented with uncommon radiological features. We did not detect any CD74-NRG1 fusion in the 109 adenocarcinoma of other subtypes, which were all negative for EGFR, KRAS, ALK, and ROS1. The CD74-NRG1 fusion mutation is rare and may be exclusively present in patients with pulmonary mucinous adenocarcinoma. Patients harboring CD74-NRG1 positive tumors may present with uncommon imaging features.

摘要

最近在非小细胞肺癌中发现了几种导致驱动融合突变的新染色体易位。肺黏液腺癌是一种罕见的非小细胞肺癌亚型,其驱动突变模式尚未得到充分研究。台湾的一项单机构队列研究旨在确定诊断为肺黏液腺癌的患者中表皮生长因子受体(EGFR)、 Kirsten大鼠肉瘤病毒癌基因同源物(KRAS)、间变性淋巴瘤激酶(ALK)、 c-ros癌基因1(ROS1)和神经调节蛋白1(NRG1)的突变情况。我们还检测了诊断为其他亚型腺癌且EGFR、KRAS、ALK和ROS1基因野生型的患者中的NRG1易位。收集了13例黏液腺癌患者的手术或活检标本。使用直接RNA测序方法,我们发现了一种罕见的CD74-NRG1融合(8%)、一种棘皮动物微管相关蛋白样4(EML4)-ALK融合(17%)和三种KRAS突变(25%)。未检测到EGFR突变或ROS1重排。罕见的CD74-NRG1融合阳性患者表现出不常见的影像学特征。在109例其他亚型腺癌中未检测到任何CD74-NRG1融合,这些腺癌的EGFR、KRAS、ALK和ROS1均为阴性。CD74-NRG1融合突变罕见,可能仅存在于肺黏液腺癌患者中。携带CD74-NRG1阳性肿瘤的患者可能表现出不常见的影像学特征。

相似文献

1
Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.台湾肺黏液腺癌的多驱动基因突变分析:罕见的CD74-NRG1易位病例的鉴定
Med Oncol. 2014 Jul;31(7):34. doi: 10.1007/s12032-014-0034-4. Epub 2014 Jun 10.
2
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.比较东亚人群中 ROS1 融合与其他驱动基因突变的肺腺癌患者的临床和预后特征。
J Thorac Oncol. 2014 Aug;9(8):1171-9. doi: 10.1097/JTO.0000000000000232.
3
Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.肺浸润性黏液腺癌的独特遗传和生存特征。
J Thorac Oncol. 2015 Aug;10(8):1156-62. doi: 10.1097/JTO.0000000000000579.
4
Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.培美曲塞为基础的化疗在 ROS1 融合阳性肺腺癌患者中的疗效与东亚人群中携带其他驱动基因突变患者的疗效比较。
J Thorac Oncol. 2016 Jul;11(7):1140-52. doi: 10.1016/j.jtho.2016.03.022. Epub 2016 Apr 16.
5
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.ROS1 重排对从不吸烟的肺腺癌患者临床结局的频率和影响。
Ann Oncol. 2013 Sep;24(9):2364-70. doi: 10.1093/annonc/mdt220. Epub 2013 Jun 19.
6
The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.ALK重排以及KRAS和EGFR突变在原发性肺黏液腺癌中的临床病理意义
Tumour Biol. 2015 Aug;36(8):6417-24. doi: 10.1007/s13277-015-3331-4. Epub 2015 Mar 28.
7
CD74-NRG1 fusions in lung adenocarcinoma.肺腺癌中的 CD74-NRG1 融合。
Cancer Discov. 2014 Apr;4(4):415-22. doi: 10.1158/2159-8290.CD-13-0633. Epub 2014 Jan 27.
8
CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.切除的非小细胞肺癌中的 CD74-ROS1 融合转录本。
Oncol Rep. 2013 Oct;30(4):1675-80. doi: 10.3892/or.2013.2630. Epub 2013 Jul 19.
9
Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.中国人群肺腺癌中新型 NRG1、EGFR 和 MET 融合基因的检测。
J Thorac Oncol. 2019 Nov;14(11):2003-2008. doi: 10.1016/j.jtho.2019.07.022. Epub 2019 Aug 2.
10
Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.中国肺腺癌患者中表皮生长因子受体(EGFR)、棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶(EML4-ALK)、 Kirsten大鼠肉瘤病毒癌基因(KRAS)和肝细胞生长因子受体(c-MET)突变分析
Exp Lung Res. 2013 Oct;39(8):328-35. doi: 10.3109/01902148.2013.819535. Epub 2013 Aug 6.

引用本文的文献

1
CT Radiomics Combined With Clinicopathological Features to Predict Invasive Mucinous Adenocarcinoma in Patients With Lung Adenocarcinoma.CT 放射组学联合临床病理特征预测肺腺癌患者浸润性黏液性腺癌。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231174306. doi: 10.1177/15330338231174306.
2
Clinicopathological Features and Survival Outcomes of Primary Pulmonary Invasive Mucinous Adenocarcinoma.原发性肺浸润性黏液腺癌的临床病理特征及生存结局
Cancers (Basel). 2021 Aug 15;13(16):4103. doi: 10.3390/cancers13164103.
3
Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma.

本文引用的文献

1
CD74-NRG1 fusions in lung adenocarcinoma.肺腺癌中的 CD74-NRG1 融合。
Cancer Discov. 2014 Apr;4(4):415-22. doi: 10.1158/2159-8290.CD-13-0633. Epub 2014 Jan 27.
2
Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy.对外周型肺癌患者行 EBUS 辅助支气管镜检查时采用废料刷检标本进行多基因分析。
Lung Cancer. 2013 Dec;82(3):420-5. doi: 10.1016/j.lungcan.2013.10.005. Epub 2013 Oct 14.
3
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.肺癌中致癌和药物敏感的 NTRK1 重排。
中国肺浸润性黏液腺癌切除标本中基因改变的基因组分析及预后价值分析
Front Oncol. 2021 Jan 11;10:603671. doi: 10.3389/fonc.2020.603671. eCollection 2020.
4
Emerging oncogenic fusions other than , , , and in NSCLC and the role of fusions as resistance mechanisms to targeted therapy.非 、 、 及 之外的非小细胞肺癌(NSCLC)中新兴的致癌融合基因以及融合基因作为靶向治疗耐药机制的作用
Transl Lung Cancer Res. 2020 Dec;9(6):2618-2628. doi: 10.21037/tlcr-20-186.
5
NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.NRG1 融合驱动的肿瘤:生物学、检测以及阿法替尼和其他 ErbB 靶向药物的治疗作用。
Ann Oncol. 2020 Dec;31(12):1693-1703. doi: 10.1016/j.annonc.2020.08.2335. Epub 2020 Sep 9.
6
Frequent fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression.磷酸化ErbB3表达预测高加索人肺黏液腺癌中的频繁融合
Oncotarget. 2018 Jan 3;9(11):9661-9671. doi: 10.18632/oncotarget.23800. eCollection 2018 Feb 9.
7
NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.法国侵袭性黏液性肺腺癌队列中的NRG1融合
Cancer Med. 2016 Dec;5(12):3579-3585. doi: 10.1002/cam4.838. Epub 2016 Oct 21.
8
Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.SLC3A2-NRG1融合在肺浸润性黏液腺癌中的致癌功能及临床意义
Oncotarget. 2016 Oct 25;7(43):69450-69465. doi: 10.18632/oncotarget.11913.
9
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.除了肺癌中的 ALK-RET、ROS1 和其他致癌基因融合。
Transl Lung Cancer Res. 2015 Apr;4(2):156-64. doi: 10.3978/j.issn.2218-6751.2014.11.11.
10
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.肺癌的转录组荟萃分析揭示了NRG1和Hippo信号通路基因的反复畸变。
Nat Commun. 2014 Dec 22;5:5893. doi: 10.1038/ncomms6893.
Nat Med. 2013 Nov;19(11):1469-1472. doi: 10.1038/nm.3352. Epub 2013 Oct 27.
4
Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation.KRAS 突变型肺黏液性腺癌的独特临床病理特征。
Hum Pathol. 2013 Dec;44(12):2636-42. doi: 10.1016/j.humpath.2013.05.026. Epub 2013 Oct 10.
5
ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR.ALK 重排肺癌在中国:临床病理、免疫组化、FISH 和 RT-PCR 的综合评估。
PLoS One. 2013 Jul 26;8(7):e69016. doi: 10.1371/journal.pone.0069016. Print 2013.
6
Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.吸烟者肺腺癌中明确的致癌驱动基因突变的频率因组织学亚型和分级吸烟剂量而异。
Lung Cancer. 2013 Jan;79(1):8-13. doi: 10.1016/j.lungcan.2012.09.018. Epub 2012 Oct 23.
7
Chipping away at the lung cancer genome.逐步破解肺癌基因组。
Nat Med. 2012 Mar 6;18(3):349-51. doi: 10.1038/nm.2697.
8
KIF5B-RET fusions in lung adenocarcinoma.肺腺癌中的 KIF5B-RET 融合。
Nat Med. 2012 Feb 12;18(3):375-7. doi: 10.1038/nm.2644.
9
RET, ROS1 and ALK fusions in lung cancer.肺癌中的 RET、ROS1 和 ALK 融合。
Nat Med. 2012 Feb 12;18(3):378-81. doi: 10.1038/nm.2658.
10
Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.女性从不吸烟者肺腺癌中驱动基因突变的频率随组织学亚型和诊断时的年龄而变化。
Clin Cancer Res. 2012 Apr 1;18(7):1947-53. doi: 10.1158/1078-0432.CCR-11-2511. Epub 2012 Feb 8.